<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2019-2-94-103</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-2219</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛЕКЦИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LECTURE</subject></subj-group></article-categories><title-group><article-title>Первичная ангиопластика и фармакоинвазивный подход в лечении инфаркта миокарда с подъемом сегмента ST на электрокардиограмме</article-title><trans-title-group xml:lang="en"><trans-title>Primary angioplasty and pharmaco-invasive strategies in the treatment of ST-elevated myocardial infarction</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0995-1924</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Глезер</surname><given-names>М. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Glezer</surname><given-names>M. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Глезер Мария Генриховна — доктор медицинских наук, профессор, профессор кафедры профилактической и неотложной кардиологии.</p><p>Москва, +7 (985) 763-04-20</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">287ast@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3559-9071</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Асташкин</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Astashkin</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Асташкин Евгений Иванович — доктор биологических наук, профессор кафедры общей патологии и патофизиологии.</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">ast-med@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО Первый МГМУ им. И. М. Сеченова Минздрава России (Сеченовский Университет)</institution></aff><aff xml:lang="en"><institution>I. M. Sechenov First Mosco w State Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздрава России</institution></aff><aff xml:lang="en"><institution>Russian Medical Academy of Continuing Professional Education</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>17</day><month>04</month><year>2019</year></pub-date><volume>18</volume><issue>2</issue><fpage>94</fpage><lpage>103</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Глезер М.Г., Асташкин Е.И., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Глезер М.Г., Асташкин Е.И.</copyright-holder><copyright-holder xml:lang="en">Glezer M.G., Astashkin E.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/2219">https://cardiovascular.elpub.ru/jour/article/view/2219</self-uri><abstract><p>Лекция посвящена выбору тактики и правилам реперфузионной терапии при инфаркте миокарда с подъемом ST на электрокардиограмме. Поскольку время реперфузии является критически важным для выживаемости пациентов и сохранения жизнеспособного миокарда, необходима правильная организация оказания помощи и четкое следование рекомендациям при медикаментозных и немедикаментозных вмешательств. В лекции обоснованы тактика фармакоинвазивного вмешательства, выбор тромболитического агента, представлена информация о показаниях и противопоказаниях к тромболитической терапии, режим дозирования тромболитических средств, других антиагрегантных и антикоагулянтных препаратов, необходимых при репефузии. Знание современных рекомендаций должно способствовать сокращению времени ишемии и случаев необоснованного отказа от эффективных вмешательств.</p></abstract><trans-abstract xml:lang="en"><p>The lecture is devoted to the choice of tactics and the rules of reperfusion therapy for ST-elevated myocardial infarction. Since the time of reperfusion is crucial for the survival of these patients and the preservation of a viable myocardium, proper organization of care and strict adherence to the guidelines for drug-induced and non-drug interventions is necessary. The lecture substantiates the tactics of pharmaco-invasive intervention, the choice of thrombolytic agent, provides data on indications and contraindications for thrombolytic therapy, dosing regimen of thrombolytic drugs, other antiplatelet and anticoagulant drugs required for reperfusion. Knowledge of current guidelines should help reduce ischemia time and cases of unjustified refusal to effective interventions.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>инфаркт миокарда</kwd><kwd>подъем сегмента ST</kwd><kwd>фармакоинвазивный подход</kwd><kwd>тромболитическая терапия</kwd><kwd>тенектеплаза</kwd></kwd-group><kwd-group xml:lang="en"><kwd>myocardial infarction</kwd><kwd>ST-segment elevation</kwd><kwd>pharmaco-invasive approach</kwd><kwd>thrombolytic therapy</kwd><kwd>tenecteplase</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST ЭКГ Кардиоваскулярная терапия и профилактика. 2007;6(8), Приложение 1.</mixed-citation><mixed-citation xml:lang="en">Clinical recommendations Diagnosis and treatment of patients with acute myocardial infarction with ST-segment elevation ECG. Cardiovascular Therapy and Prevention. 2007;6(8), Prilozhenie 1. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Скорая медицинская помощь. Клинические рекоменда-ции/под ред. С. Ф. Багненко. М.: ГЭОТАР-Медиа, 2015. 872 с. ISBN 978-5-97043447-5.</mixed-citation><mixed-citation xml:lang="en">Emergency. Clinical recommendations. Ed. S. F. Bagnenko. M.: GEOTAR-Media, 2015. 872 p. (in Russ.). ISBN 978-5-97043447-5.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77 doi:10.1093/eurheartj/ehx393.</mixed-citation><mixed-citation xml:lang="en">Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77 doi:10.1093/eurheartj/ehx393.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Danchin N, Coste P, Ferrieres J, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction. Data from the French Registry on Acute ST-Elevation Myocardial Infarction (FAST-MI). Circulation. 2008;118(3):268-76. doi:10.1161/CIRCULATIONAHA.107762765.</mixed-citation><mixed-citation xml:lang="en">Danchin N, Coste P, Ferrieres J, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction. Data from the French Registry on Acute ST-Elevation Myocardial Infarction (FAST-MI). Circulation. 2008;118(3):268-76. doi:10.1161/CIRCULATIONAHA.107762765.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Васильева Е. Ю., Плавунов Н. Ф., Калинская А. И. и др. Организация “инфарктной сети” в Москве и результаты ее работы за пятилетний период. Эндоваскулярная хирургия. 2018;5(2):288-94.</mixed-citation><mixed-citation xml:lang="en">Vasil'eva EYu, Plavunov NF, Kalinskaya AI, et al. Organization of “heart attack network” in Moscow and the results of its work for a five-year period. Endovaskulyarnaya hirurgiya. 2018;5(2):288-94. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Барбараш О. Л., Кашталап В. В. Место фармакоинвазивной тактики ведения пациентов с острым коронарным синдромом с подъемом сегмента ST в России. Кардиология. 2014;54(9):79-85.</mixed-citation><mixed-citation xml:lang="en">Barbarash OL, Kashtalap VV. The place of pharmacoinvasive management in patients with ST-elevation acute coronary syndrome in Russia. Kardiologiia. 2014;54(9):79-85. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Артамонова Г. В., Херасков В. Ю., Крючков Д.В и др. Подход к организации помощи больным с инфарктом миокарда — “кемеровская модель”. Компл пробл сердечно-сосудистых забол. 2013;1:55-9.</mixed-citation><mixed-citation xml:lang="en">Artamonova GV, Heraskov VYu, Kryuchkov DV, et al. The approach to organizing care for patients with myocardial infarction is the “Kemerovo model”. Kompl probl serdechno-sosudistyh zabol. 2013;1:55-9. (In Russ)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">. Бокерия Л. А., Ключников И. В., Чигогидзе Н. А. и др. Влияние срока после тромболитической терапии на результаты стентирования коронарных артерий у больных с инфарктом миокарда. Бюл НЦССХ им. А.Н. Бакулева РАМН. 2013;6:46-50.</mixed-citation><mixed-citation xml:lang="en">.	Bokeriya LA, Klyuchnikov IV, CHigogidze NA, et al. The effect of time after thrombolytic therapy on the results of coronary artery stenting in patients with myocardial infarction. Byul NCSSKH im. A. N. Bakuleva RAMN. 2013;6:46-50. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Pinto DS, Frederick PD, Chakrabarti AK, et al, National Registry of Myocardial Infarction Investigators. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation. 2011;124(23):2512-21. doi:10.1161/CIRCULATIONAHA.111.018549.</mixed-citation><mixed-citation xml:lang="en">Pinto DS, Frederick PD, Chakrabarti AK, et al, National Registry of Myocardial Infarction Investigators. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation. 2011;124(23):2512-21. doi:10.1161/CIRCULATIONAHA.111.018549.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Armstrong PW, Gershlick AH, Goldstein P, et al. STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368(15):1379-87. doi:10.1056/NEJMoa1301092.</mixed-citation><mixed-citation xml:lang="en">Armstrong PW, Gershlick AH, Goldstein P, et al. STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368(15):1379-87. doi:10.1056/NEJMoa1301092.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343(8893):311-22. doi:10.1016/S0140-6736(94)91161-4.</mixed-citation><mixed-citation xml:lang="en">Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343(8893):311-22. doi:10.1016/S0140-6736(94)91161-4.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996 Sep 21;348(9030):771-5. doi:10.1016/S0140-6736(96)02514-7.</mixed-citation><mixed-citation xml:lang="en">Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996 Sep 21;348(9030):771-5. doi:10.1016/S0140-6736(96)02514-7.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">White HD. Thrombolytic therapy in the elderly. Lancet. 2000;356(9247):2028-30. doi:10.1016/S0140-6736(00)03397-3.</mixed-citation><mixed-citation xml:lang="en">White HD. Thrombolytic therapy in the elderly. Lancet. 2000;356(9247):2028-30. doi:10.1016/S0140-6736(00)03397-3.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Carville S, Harker M, Henderson R, Gray H. Guideline Development Gro Acute management of myocardial infarction with ST-segment elevation: summary of NICE guidance. BMJ. 2013 Jul 10;347:f4006. doi:10.1136/bmj.f4006.</mixed-citation><mixed-citation xml:lang="en">Carville S, Harker M, Henderson R, Gray H. Guideline Development Gro Acute management of myocardial infarction with ST-segment elevation: summary of NICE guidance. BMJ. 2013 Jul 10;347:f4006. doi:10.1136/bmj.f4006.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JACC. 2013;61(4):e78-140. doi:10.1016/j.jacc.2012.11.019.</mixed-citation><mixed-citation xml:lang="en">O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JACC. 2013;61(4):e78-140. doi:10.1016/j.jacc.2012.11.019.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Danchin N, Blanchard D, Steg PG, et al.; USIC 2000 Investigators. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation. 2004;110:1909-15. doi:10.1161/01.CIR.0000143144.82338.36.</mixed-citation><mixed-citation xml:lang="en">Danchin N, Blanchard D, Steg PG, et al.; USIC 2000 Investigators. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation. 2004;110:1909-15. doi:10.1161/01.CIR.0000143144.82338.36.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Murphy SA, Gibson CM, Van de Werf F, et al. Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I). Am J Cardiol. 2002;90(1):51-4. doi:101016/S0002-9149(02)02387-1.</mixed-citation><mixed-citation xml:lang="en">17 Murphy SA, Gibson CM, Van de Werf F, et al. Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I). Am J Cardiol. 2002;90(1):51-4. doi:101016/S0002-9149(02)02387-1.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Armstrong PW, Zheng Y, Westerhout CM, et al. STREAM investigators. Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trial. Am Heart J. 2015;169(6):890-8.e1. doi:10.1016/j.ahj.2015.03.011.</mixed-citation><mixed-citation xml:lang="en">Armstrong PW, Zheng Y, Westerhout CM, et al. STREAM investigators. Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trial. Am Heart J. 2015;169(6):890-8.e1. doi:10.1016/j.ahj.2015.03.011.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Lanaro E, Caixeta A, Soares JA, et al. Influence of gender on the risk of death and adverse events in patients with acute myocardial infarction undergoing pharmacoinvasive strategy. J Thromb Thrombolysis. 2014;38(4):510-6. doi:101007/s11239-014-1072-7.</mixed-citation><mixed-citation xml:lang="en">Lanaro E, Caixeta A, Soares JA, et al. Influence of gender on the risk of death and adverse events in patients with acute myocardial infarction undergoing pharmacoinvasive strategy. J Thromb Thrombolysis. 2014;38(4):510-6. doi:101007/s11239-014-1072-7.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Bainey KR, Ferguson C, Ibrahim QI, et al. Vital Heart Response Registry Investigators. Impact of reperfusion strategy on aborted myocardial infarction: insights from a large Canadian ST-Elevation Myocardial Infarction Clinical Registry. Can J Cardiol. 2014;30(12):1570-5. doi:10.1016/j.cjca.2014.08.021.</mixed-citation><mixed-citation xml:lang="en">Bainey KR, Ferguson C, Ibrahim QI, et al. Vital Heart Response Registry Investigators. Impact of reperfusion strategy on aborted myocardial infarction: insights from a large Canadian ST-Elevation Myocardial Infarction Clinical Registry. Can J Cardiol. 2014;30(12):1570-5. doi:10.1016/j.cjca.2014.08.021.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Dianati Maleki N, Van de Werf F, Goldstein P, et al. Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial. Heart. 2014;100(19):1543-9. doi:10.1136/heartjnl-2014-306023.</mixed-citation><mixed-citation xml:lang="en">Dianati Maleki N, Van de Werf F, Goldstein P, et al. Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial. Heart. 2014;100(19):1543-9. doi:10.1136/heartjnl-2014-306023.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Shavadia J, Zheng Y, Dianati Maleki N, et al. Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? J Am Heart Assoc. 2015;4(8):e002049. doi: 10.1161/JAHA.115.002049.</mixed-citation><mixed-citation xml:lang="en">Shavadia J, Zheng Y, Dianati Maleki N, et al. Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? J Am Heart Assoc. 2015;4(8):e002049. doi: 10.1161/JAHA.115.002049.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Bundhun PK, Janoo G, Chen MH. Bleeding events associated with fibrinolytic therapy and primary percutaneous coronary intervention in patients with STEMI: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(23): e3877. doi:10.1097/MD.0000000000003877.</mixed-citation><mixed-citation xml:lang="en">Bundhun PK, Janoo G, Chen MH. Bleeding events associated with fibrinolytic therapy and primary percutaneous coronary intervention in patients with STEMI: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(23): e3877. doi:10.1097/MD.0000000000003877.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Guillermin A, Yan DJ, Perrier A, Marti C. Safety and efficacy of tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-analysis of randomized trials. Arch Med Sci. 2016;12(6):1181-7. doi:10.5114/aoms.2016.58929.</mixed-citation><mixed-citation xml:lang="en">Guillermin A, Yan DJ, Perrier A, Marti C. Safety and efficacy of tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-analysis of randomized trials. Arch Med Sci. 2016;12(6):1181-7. doi:10.5114/aoms.2016.58929.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Liu F, Guo Q, Xie G, et al. Percutaneous Coronary Intervention after Fibrinolysis for ST-Segment Elevation Myocardial Infarction Patients: An Updated Systematic Review and Meta-Analysis. PLoS One. 2015;10(11):e0141855. doi:10.1371/journal.pone.0141855.</mixed-citation><mixed-citation xml:lang="en">Liu F, Guo Q, Xie G, et al. Percutaneous Coronary Intervention after Fibrinolysis for ST-Segment Elevation Myocardial Infarction Patients: An Updated Systematic Review and Meta-Analysis. PLoS One. 2015;10(11):e0141855. doi:10.1371/journal.pone.0141855.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Jaffe R, Halon DA, Karkabi B, et al. Thrombolysis Followed by Early Revascularization: An Effective Reperfusion Strategy in Real World Patients with ST-Elevation Myocardial Infarction Cardiology. 2007;107:329-36. doi:10.1159/000099070.</mixed-citation><mixed-citation xml:lang="en">Jaffe R, Halon DA, Karkabi B, et al. Thrombolysis Followed by Early Revascularization: An Effective Reperfusion Strategy in Real World Patients with ST-Elevation Myocardial Infarction Cardiology. 2007;107:329-36. doi:10.1159/000099070.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Rashid MK, Guron N, Bernick J, et al. Safety and Efficacy of a Pharmacoinvasive Strategy in ST-Segment Elevation Myocardial Infarction: A Patient Population Study Comparing a Pharmacoinvasive Strategy With a Primary Percutaneous Coronary Intervention Strategy Within a Regional System. JACC Cardiovasc Interv. 2016;9(19): 2014-20. doi:10.1016/j.jcin.2016.07.004.</mixed-citation><mixed-citation xml:lang="en">Rashid MK, Guron N, Bernick J, et al. Safety and Efficacy of a Pharmacoinvasive Strategy in ST-Segment Elevation Myocardial Infarction: A Patient Population Study Comparing a Pharmacoinvasive Strategy With a Primary Percutaneous Coronary Intervention Strategy Within a Regional System. JACC Cardiovasc Interv. 2016;9(19): 2014-20. doi:10.1016/j.jcin.2016.07.004.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Sim DS, Jeong MH, Ahn Y, et al. Korea Acute Myocardial Infarction Registry (KAMIR) Investigators. Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction: A Propensity Score-Matched Analysis. Circ Cardiovasc Interv. 2016;9(9). pii:e003508. doi:10.1161/CIRCINTERVENTIONS.115.003508.</mixed-citation><mixed-citation xml:lang="en">Sim DS, Jeong MH, Ahn Y, et al. Korea Acute Myocardial Infarction Registry (KAMIR) Investigators. Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction: A Propensity Score-Matched Analysis. Circ Cardiovasc Interv. 2016;9(9). pii:e003508. doi:10.1161/CIRCINTERVENTIONS.115.003508.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Pu J, Ding S, Ge H, et al. EARLY-MYO Investigators. Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction). Circulation. 2017;136(16):1462-73. doi:10.1161/CIRCULATIONAHA.117.030582.</mixed-citation><mixed-citation xml:lang="en">Pu J, Ding S, Ge H, et al. EARLY-MYO Investigators. Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction). Circulation. 2017;136(16):1462-73. doi:10.1161/CIRCULATIONAHA.117.030582.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation. 2006;114:2019-25. doi:10.1161/CIRCULATIONAHA.106.638353.</mixed-citation><mixed-citation xml:lang="en">Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation. 2006;114:2019-25. doi:10.1161/CIRCULATIONAHA.106.638353.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Siddiqi TJ, Usman MS, Khan MS, et al. Meta-Analysis Comparing Primary Percutaneous Coronary Intervention Versus Pharmacoinvasive Therapy in Transfer Patients with ST-Elevation Myocardial Infarction. Am J Cardiol. 2018;122(4):542-7. doi:10.1016/j.amjcard.2018.04.057.</mixed-citation><mixed-citation xml:lang="en">Siddiqi TJ, Usman MS, Khan MS, et al. Meta-Analysis Comparing Primary Percutaneous Coronary Intervention Versus Pharmacoinvasive Therapy in Transfer Patients with ST-Elevation Myocardial Infarction. Am J Cardiol. 2018;122(4):542-7. doi:10.1016/j.amjcard.2018.04.057.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Berwanger O, Nicolau JC, Carvalho AC, et al. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. Am Heart J. 2018;202:89-96. doi:10.1016/j.ahj.2018.02.017.</mixed-citation><mixed-citation xml:lang="en">Berwanger O, Nicolau JC, Carvalho AC, et al. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. Am Heart J. 2018;202:89-96. doi:10.1016/j.ahj.2018.02.017.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
